[卡介苗用于浅表性膀胱癌。作者的经验]
[BCG in superficial carcinoma of the bladder. Authors' experience].
作者信息
Bordalba Gómez J R, Muñoz Segui J, Aguilo F, Gil Vernet A, Vigues F, Lopez Costea M A, Serrallach N
机构信息
Servicio de Urología, Hospital de Bellvitge, Ciudad Sanitaria Princeps d'Espanya, Barcelona.
出版信息
Actas Urol Esp. 1992 Jun;16(6):443-5.
Contribution of 95 patients with surface vesical tumour managed with UTR and endovesical BCG. The response was absence of recurrence in 68.4% cases in Ta stage, 63% in T1 and 66.7% in 'in situ' carcinoma. Therapy tolerability was good, with few side-effects. We conclude that BCG endovesical instillation as co-adjunctive therapy to UTR in surface vesical tumours has been shown to be effective for the period under study.
95例浅表性膀胱肿瘤患者接受经尿道膀胱肿瘤切除术（UTR）联合膀胱内卡介苗（BCG）治疗的疗效。Ta期患者的复发率为68.4%，T1期为63%，原位癌为66.7%。治疗耐受性良好，副作用较少。我们得出结论，在本研究期间，膀胱内灌注卡介苗作为UTR治疗浅表性膀胱肿瘤的辅助治疗已被证明是有效的。
Zotero 插件